Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 170, Issue 3, 2014, Pages 401-409

  Tosi, Flavia ^a   Di Sarra, Daniela ^a   Bonin, Cecilia ^b   Zambotti, Francesca ^a   Dall'Alda, Marlene ^a   Fiers, Tom ^c   Kaufman, Jean Marc ^c,d   Donati, Matilde ^a   Franchi, Massimo ^b   Zanolin, Maria Elisabetta ^e   Bonora, Enzo ^a   Moghetti, Paolo ^a  

^a Section of Endocrinology   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c Laboratory for Hormonology   (Italy)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; C REACTIVE PROTEIN; FOLLITROPIN; GLUCOSE; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LUTEINIZING HORMONE; PENTRAXIN 3; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANDROGEN BLOOD LEVEL; ANOVULATION; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUILIBRIUM DIALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HOMA IR; HUMAN; HYPERANDROGENISM; INSULIN SENSITIVITY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METABOLIC PARAMETERS; OBESITY; OLIGOANOVULATION; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERANDROGENISM; POLYCYSTIC OVARY SYNDROME; SERUM AMYLOID P-COMPONENT;

EID: 84896282570     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0761     Document Type: Article

References (45)

1. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. (doi:10.1210/jc.2009-2724)
2. Diamanti-Kandarakis E, Paterakis T & Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Annals of the New York Academy of Sciences 2006 1092 175-186. (doi:10.1196/annals.1365.015)
3. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N & Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocrine Reviews 2012 33 812-841. (doi:10.1210/er.2012-1003)
4. Pepys MB & Hirschfield GM. C-reactive protein: a critical update. Journal of Clinical Investigation 2003 111 1805-1812. (doi:10.1172/JCI18921)
5. Buckley DI, Fu R, Freeman M, Rogers K & Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2009 151 483-495. (doi:10.7326/0003-4819-151-7-200910060-00009)
6. Escobar-Morreale HF, Luque-Ramírez M & González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertility and Sterility 2011 95 1048-1058. (doi:10.1016/j.fertnstert.2010.11.036)
7. Mantovani A, Garlanda C, Doni A & Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. Journal of Clinical Immunology 2008 28 1-13. (doi:10.1007/s10875-007-9126-7)
8. Jenny NS, Arnold A, Kuller L, Russell T & Psaty B. Associations of pentraxin 3 with cardiovascular disease and all-cause death. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 594-599. (doi:10.1161/ATVBAHA.108. 178947)
9. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M & Peralta CA. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. American Heart Journal 2012 163 274-279. (doi:10.1016/j.ahj.2011. 11.007)
10. Ryu WS, Kim CK, Kim BJ, Kim C, Lee SH & Yoon BW. Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis 2012 220 581-586. (doi:10.1016/j.atherosclerosis.2011.11.036)
11. Garlanda C, Maina V, Cotena A & Moalli F. The soluble pattern recognition receptor pentraxin-3 in innate immunity, inflammation and fertility. Journal of Reproductive Immunology 2009 83 128-133. (doi:10.1016/j.jri.2009.05. 006)
12. Inforzato A, Jaillon S, Moalli F, Barbati E, Bonavita E, Bottazzi B, Mantovani A & Garlanda C. The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. Tissue Antigens 2011 77 271-282. (doi:10.1111/j.1399-0039.2011.01645.x)
13. Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, Doni A, Bastone A, Mantovani G, Beck-Pecoz P et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in vivo fertilization. Development 2004 131 1577-1586. (doi:10.1242/dev.01056)
14. Scarchilli L, Camaioni A, Bottazzi B, Negri V, Doni A, Deban L, Bastone A, Salvatori G, Mantovani A, Siracusa G et al. PTX3 interacts with inter-α-trypsin inhibitor: implications for hyaluronan organization and cumulus oophurus expansion. Journal of Biological Chemistry 2007 282 30161-30170. (doi:10.1074/jbc.M703738200)
15. Aydogdu A, Tasci I, Tapan S, Basaran Y, Aydogan U, Meric C, Sonmez A, Aydogdu S, Akbulut H, Taslipinar A et al. High plasma level of long pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology 2012 28 722-725. (doi:10.3109/09513590.2011.652719)
16. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Fertility and Sterility 2004 81 19-25.
17. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli V, Zambotti F, Dall'Alda M, Spiazzi G, Zanolin ME et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2013 98 E628-E637. (doi:10.1210/jc.2012-3908)
18. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF & Futterweit W. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility 2009 91 456-488. (doi:10.1016/j.fertnstert.2008.06.035)
19. Hatch R, Rosenfield RL, Kim MH & Tredway D. Hirsutism: implications, etiology, and management. American Journal of Obstetrics and Gynecology 1981 140 815-830. (Pubitemid 11046650)
20. Matthews DR, Hosker JP, Rudenski AS, Maylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
21. DeFronzo RA, Tobin JD & Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 1979 237 E214-E223. (Pubitemid 9249478)
22. Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini F, Muggeo M & Moghetti P. Body fat and insulin resistance independently predict serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. European Journal of Endocrinology 2009 161 737-745. (doi:10.1530/EJE-09-0379)
23. Gray DS, Bray GA, Gemayel N & Kaplan K. Effect of obesity on bioelectrical impendance. American Journal of Clinical Nutrition 1989 50 255-260.
24. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672. (doi:10.1210/jc.84.10.3666)
25. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
26. Doni A, Michela M, Bottazzi B, Peri G, Valentino S, Polentarutti N, Garlanda C & Mantovani A. Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells. Stimulation by IL-10 and inhibition by IFN-γ. Journal of Leukocyte Biology 2006 79 797-802. (doi:10.1189/jlb. 0905493)
27. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, D'Auria F, Praderio L, Ciboddo G, Sabbadini MG et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis and Rheumatism 2001 44 2841-2850. (doi:10.1002/1529-0131(200112)44: 12〈2841::AID-ART472〉3.0.CO;2-6)
28. Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Iida H, Takahashi H, Kirikoshi H et al. Plasma pentraxin 3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterology 2008 8 53. (doi:10.1186/1471-230X-8-53)
29. Lim SS, Norman RJ, Davies MJ & Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obesity Reviews 2012 14 95-109. (doi:10.1111/j.1467-789X.2012.01053.x)
30. Piltonen T, Puurunen J, Hedberg P, Ruokonen A, Mutt SJ, Herzig KH, Nissinen A, Morin-Papunen L & Tapanainen JS. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study. Human Reproduction 2012 27 3046-3056. (doi:10.1093/humrep/ des225)
31. Gonzalez F, Sia CL, Stanczyk FZ, Blair HE & Krupa ME. Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. Endocrine 2012 42 726-735. (doi:10.1007/s12020-012- 9728-6)
32. Malkin CJ, Pugh PJ, Jones RD, Jones TH & Channer KS. Testosterone as a protective factor against atherosclerosis-immunomodulation and influence upon plaque development and stability. Journal of Endocrinology 2003 178 373-380. (doi:10.1677/joe.0.1780373)
33. Pergola C, Rogge A, Dodt G, Northoff H, Weinigel C, Barz D, Rådmark O, Sautebin L & Werz O. Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. FASEB Journal 2011 25 3377-3387. (doi:10.1096/fj.11-182758)
34. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T & Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clinical Chemistry and Laboratory Medicine 2009 47 471-477. (doi:10.1515/CCLM.2009.110)
35. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocrine Reviews 2003 24 302-312. (doi:10.1210/er.2003- 0004)
36. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H & Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circulation Research 1999 84 813-819. (doi:10.1161/01.RES.84.7.813)
37. Hanke H, Lenz C, Hess B, Spindler KD & Weidemann W. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 2001 103 1382-1385. (doi:10.1161/01.CIR.103. 10.1382)
38. Bernini GP, Sgrò M, Moretti A, Argenio GF, Barlascini CO, Cristofani R & Salvetti A. Endogenous androgens and carotid intimal-medial thickness in women. Journal of Clinical Endocrinology and Metabolism 1999 84 2008-2012. (doi:10.1210/jc.84.6.2008)
39. Bernini GP, Moretti A, Sgrò M, Argenio GF, Barlascini CO, Cristofani R & Salvetti A. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001 1 43-50. (doi:10.1097/00042192- 200101000-00008)
40. Norata GD, Garlanda C & Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends in Cardiovascular Medicine 2010 20 35-40. (doi:10.1016/j.tcm.2010.03.005)
41. Yudkin JS, Stehouwer CD, Emeis JJ & Coppack SW. C- reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 972-978. (doi:10.1161/01.ATV.19.4.972)
42. Varani S, Elvin JA, Yan C, DeMayo J, DeMayo FJ, Horton HF, Byrne MC & Matzuk MM. Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. Molecular Endocrinology 2002 16 1154-1167. (doi:10.1210/me.16.6.1154)
43. Yang J-L, Zhang C-P, Li L, Huang L, Ji S-Y, Lu C-L, Fan C-H, Cai H, Ren Y, Hu Z-Y et al. Testosterone induces redistribution of forkhead box-3a and down-regulation of growth and differentiation factor 9 messenger ribonucleic acid expression at early stage of mouse folliculogenesis. Endocrinology 2010 151 774-782. (doi:10.1210/en.2009-0751)
44. Zhao SY, Qiao J, Chen YJ, Liu P, Li J & Yan J. Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome. Fertility and Sterility 2010 94 261-267. (doi:10.1016/j.fertnstert.2009.03.014)
45. Wei LN, Liang XY, Fang C & Zhang MF. Abnormal expression of growth differentiation factor 9 and bone morphogenetic protein 15 in stimulated oocytes during maturation from women with polycystic ovary syndrome. Fertility and Sterility 2011 96 464-468. (doi:10.1016/j.fertnstert.2011.05.036)